Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
Event: | Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day | |
Date: | April 27, 2017 | |
Time: | 4:15 pm EDT | |
Location: | Boston, MA |
A live and replay video webcast of the presentation will be available at http://www.arminvestorday.com/webcast.
About
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Contacts for Adverum:Leone Patterson Chief Financial OfficerAdverum Biotechnologies, Inc. 650-665-7222 lpatterson@adverum.comJill Steier Senior Vice PresidentThe Trout Group LLC 646-378-2946 jsteier@troutgroup.com